Early Neurovascular Adaptations in Aging Women
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Jul 22, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Early Neurovascular Adaptations in Aging Women," is focused on understanding how blood vessels change in response to aging in women. Specifically, it looks at the role of the sympathetic nervous system, which is part of the body's automatic control system that affects things like heart rate and blood flow. The researchers aim to learn more about these changes, especially since they can impact health as women age.
The study is currently recruiting women aged 18 to 55 who were assigned female at birth. However, there are some important requirements to be eligible. For instance, women who are pregnant, breastfeeding, or have certain health conditions may not qualify. Participants can expect to take part in various assessments that will help researchers gather information about their vascular health. This trial is a valuable opportunity to contribute to our understanding of how aging affects women's health, potentially leading to better care and treatments in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Assigned female at birth (AFAB)
- • 18-55 years of age
- Exclusion Criteria:
- • Assigned male at birth (AMAB)
- • Pregnancy, breastfeeding
- • Body mass index ≥30 kg/m2
- • Taking medications known to affect metabolic, autonomic, and/or respiratory function
- • Oral hormonal contraception in last 6 month
- • History of hormone replacement therapy
- • History of hyster- or oophor-ectomy
- • Current smoking/Nicotine use
- • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
- • Chronic disease
- • Blood pressure ≥140/90 mmHg
- • Communication barriers
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbia, Missouri, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported